Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.
Bottom Line: In contrast, patients with a negative or weak delayed type hypersensitivity had a median disease free survival of 9 months (relative risk of recurrence=4.5, P=0.001), and a median overall survival of 16 months (relative risk of death=15, P=0.001).Stage III patients with a positive delayed type hypersensitivity reaction had an improved disease free survival of 16 months and a mean overall survival of 38 months, whereas patients with a negative delayed type hypersensitivity had a median disease free survival of 7 months (relative risk=4.5, P=0.02) and a median overall survival of 16 months (relative risk=9.5, P=0.005).The adjuvant administration of autologous melanoma vaccine was associated with improved disease-free and overall survival to selected patients who successfully attained anti-melanoma reactivity as detected by positive delayed type hypersensitivity reactions to unmodified melanoma cells.
Affiliation: Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel 91120. firstname.lastname@example.orgShow MeSH
Related in: MedlinePlus
Mentions: Current patient status with respect to DTH response. The number of patients in each of three categories. NED: no evidence of disease; AWD: alive with disease; Exitus: deceased. In each of these categories, the patients were divided into two groups according to the pattern of the delayed type hyper-sensitivity (DTH).
Affiliation: Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel 91120. email@example.com